Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M193,146Revenue $M51,584Net Margin (%)20.7Z-Score2.6
Enterprise Value $M198,420EPS $3.2Operating Margin %26.8F-Score6
P/E(ttm))19.2Cash Flow Per Share $3.5Pre-tax Margin (%)26.8Higher ROA y-yN
Price/Book2.510-y EBITDA Growth Rate %3.2Quick Ratio2.4Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %8.5Current Ratio2.7Lower Leverage y-yN
Price/Cash Flow7.2y-y EBITDA Growth Rate %2.3ROA % (ttm)6.0Higher Current Ratio y-yY
Dividend Yield %3.4Insider Buy (3m)0ROE % (ttm)13.6Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M6,379ROI % (ttm)21.6Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEVanguard Health Care Fund 2014-06-30 Add0.62%$29.02 - $32.4
($30.05)
$ 30.72%Add 105.23%14,934,022
PFEJoel Greenblatt 2014-06-30 Add0.27%$29.02 - $32.4
($30.05)
$ 30.72%Add 71.59%1,741,314
PFECharles Brandes 2014-06-30 Add0.12%$29.02 - $32.4
($30.05)
$ 30.72%Add 5.78%6,075,460
PFERay Dalio 2014-06-30 Add0.06%$29.02 - $32.4
($30.05)
$ 30.72%Add 250.56%393,008
PFEMichael Price 2014-06-30 Reduce-0.97%$29.02 - $32.4
($30.05)
$ 30.72%Reduce -69.14%107,100
PFEDodge & Cox 2014-06-30 Reduce-0.5%$29.02 - $32.4
($30.05)
$ 30.72%Reduce -23.73%48,902,097
PFEJean-Marie Eveillard 2014-06-30 Reduce-0.47%$29.02 - $32.4
($30.05)
$ 30.72%Reduce -70.71%2,303,762
PFEJohn Hussman 2014-06-30 Sold Out -0.04%$29.02 - $32.4
($30.05)
$ 30.72%Sold Out0
PFEJoel Greenblatt 2014-03-31 Add0.38%$29.66 - $32.75
($31.39)
$ 30.7-2%Add 356.54%1,014,808
PFEJohn Hussman 2014-03-31 Buy 0.04%$29.66 - $32.75
($31.36)
$ 30.7-2%New holding, 17000 sh.17,000
PFEVanguard Health Care Fund 2014-03-31 Reduce-0.48%$29.66 - $32.75
($31.36)
$ 30.7-2%Reduce -40.13%7,276,622
PFEJean-Marie Eveillard 2014-03-31 Reduce-0.19%$29.66 - $32.75
($31.39)
$ 30.7-2%Reduce -22.77%7,866,473
PFEJean-Marie Eveillard 2013-12-31 Add0.16%$28.24 - $32.2
($30.7)
$ 30.70%Add 23.07%10,186,005
PFEJoel Greenblatt 2013-12-31 Add0.11%$28.24 - $32.2
($30.7)
$ 30.70%Add 241.71%222,280
PFERonald Muhlenkamp 2013-12-31 Add0.05%$28.24 - $32.2
($30.7)
$ 30.70%Add 29.15%45,129
PFERay Dalio 2013-12-31 Add0.01%$28.24 - $32.2
($30.7)
$ 30.70%Add 102.18%110,408
PFEVanguard Health Care Fund 2013-12-31 Reduce-0.91%$28.24 - $32.2
($30.7)
$ 30.70%Reduce -43.19%12,153,122
PFECharles Brandes 2013-12-31 Reduce-0.22%$28.24 - $32.2
($30.7)
$ 30.70%Reduce -9.32%5,767,402
PFEDavid Dreman 2013-12-31 Reduce-0.15%$28.24 - $32.2
($30.7)
$ 30.70%Reduce -85.73%10,163
PFEDonald Yacktman 2013-12-31 Sold Out -0.01%$28.24 - $32.2
($30.7)
$ 30.70%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PFE Ray Dalio 2014-06-30393,0080.010.09+250.56%
PFE Vanguard Health Care Fund 2014-06-3014,934,0220.231.2+105.23%
PFE Joel Greenblatt 2014-06-301,741,3140.030.65+71.59%
PFE David Dreman 2014-06-3013,61500.03+14.88%
PFE Charles Brandes 2014-06-306,075,4600.12.2+5.78%
PFE James Barrow 2014-06-3060,500,0580.952.4+1.01%
PFE Prem Watsa 2014-06-30235,00000.48
PFE Ruane Cunniff 2014-06-3010,98700-0.32%
PFE Ronald Muhlenkamp 2014-06-3041,01900.21-0.36%
PFE Mario Gabelli 2014-06-301,104,0700.020.17-5.28%
PFE John Keeley 2014-06-3089,83900.05-6.31%
PFE Dodge & Cox 2014-06-3048,902,0970.771.4-23.73%
PFE Michael Price 2014-06-30107,10000.39-69.14%
PFE Jean-Marie Eveillard 2014-06-302,303,7620.040.17-70.71%
PFE John Hussman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OLSON LAURIE JExecutive Vice President 2014-06-12Sell36,275$29.533.56view
Germano Geno JGroup President 2014-06-02Sell30,000$29.683.03view
YOUNG JOHN DGroup President 2014-03-17Sell9,000$31.38-2.55view
PFIZER INC10% Owner 2014-03-12Buy272,727$11178view
CANGIALOSI LORETTA VSr. Vice President, Controller 2014-03-04Sell102,943$32.05-4.59view
Dolsten MikaelPresident R&D 2014-03-04Sell35,789$32.58-6.14view
SUSMAN SALLYExecutive Vice President 2014-03-04Sell67,585$32.59-6.17view
PFIZER INC10% Owner 2014-02-04Buy227,261$8282.25view
DAMELIO FRANK AExecutive Vice President 2014-01-13Sell131,810$30.82-0.78view
DAMELIO FRANK AExecutive Vice President 2014-01-13Sell28,190$30.86-0.91view

Press Releases about PFE :

    Quarterly/Annual Reports about PFE:

      News about PFE:

      Articles On GuruFocus.com
      The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead Sep 16 2014 
      The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead Sep 16 2014 
      I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
      Higher Yielding Stocks With A Cheap EV/EBITDA Ratio And Low Debt Figures Aug 28 2014 
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG Aug 18 2014 
      A Strong Candidate for Investor´s Portfolios Aug 12 2014 
      Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
      Widely Held Guru Stocks Near 52-Week Lows Aug 05 2014 
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, UBS Aug 04 2014 
      Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 


      More From Other Websites
      Merck Enters into Licensing Agreement with Sun Pharma Sep 18 2014
      FDA OKs faster-acting label for ED drug Stendra Sep 18 2014
      FDA OKs faster-acting label for ED drug Stendra Sep 18 2014
      French cancer immunotherapy specialist OSE Pharma prepares IPO Sep 18 2014
      French cancer immunotherapy specialist OSE Pharma prepares IPO Sep 18 2014
      Bayer to float plastics business and focus on life sciences Sep 18 2014
      Isis Pharmaceuticals CEO: Not changing name, terrorists c... Sep 17 2014
      Alzheimer's drug fight Sep 16 2014
      These Two Companies Could Be Pfizer's Top Targets Sep 15 2014
      Takeover Panel proposes tougher rules for deal promises Sep 15 2014
      Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor Sep 12 2014
      Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor Sep 12 2014
      Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor Sep 12 2014
      Pfizer CEO is Still Weighing Inversion Deals Sep 12 2014
      Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies Sep 12 2014
      Pfizer says 'window still open' for tax inversions Sep 11 2014
      7 Pictures Are Worth 20 Prudent Speculator Stock Picks Sep 11 2014
      Pfizer Inc. Trying To Claw Its Way Back Up After Pullback Sep 10 2014
      Martoma's Nine-Year Sentence Reflects Outsized Insider Trading Gains Sep 09 2014
      [video] As Life Expectancies Rise, Death Care Stocks Offer Opportunities Sep 09 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      SEENSCO
      ReplySEENSCO - 3 months ago
      PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK